LSE:HLN 19 May 2026 - 6 July 2026

Haleon PLC gained on Wednesday as the FTSE 100 traded lower. Traders focused on Haleon’s buyback, with the share count dropping quickly. It looks like the bulk of this year’s cash return is already spent before first-half results come out. Haleon ended the day at 350.50 pence, up 2.80 pence, or 0.81%. Trading volume was 22.6 million shares, with on-book turnover at about 65.6 million pounds, according to London Stock Exchange data. The FTSE 100 dropped 18.78 points, or 0.18%, to 10,478.34.

Haleon PLC was last trading above the price set in its latest buyback, raising questions late Friday about how much lift the £500 million repurchase will give shares after a fast climb earlier in the week. The stock stood at 349.10p/349.20p, up 1.00p, near 16:04 BST. The London Stock Exchange’s session runs from 08:00 to 16:30 BST. Haleon jumped 4.29% to £3.48 on Wednesday, topping the FTSE 100, which was up just 0.31%, MarketWatch reported. The stock is still down 16.37% from its 52-week high of £4.16 hit on Feb. 18. Trading volume came in at 22.2 million shares, short of the 50-day average of 25.3 million.

Haleon PLC was flat around 348 pence Thursday, after gaining 4.3% the day before. The FTSE 100 was up 0.45% in the afternoon. Haleon shares bounced even as JPMorgan Chase & Co cut its price target to 315p from 335p and stuck with an underweight. That new target is about 9.5% under where the stock traded Thursday. A June 18 LSEG poll showed a median target of 422.5p, up 21.4% versus the shares, with targets from 325p to 512p. JPMorgan has now moved its target under even that prior range.

Haleon traded at 341 pence, gaining 2.2%, in delayed action in London around 9:08 a.m. BST. The FTSE 100 showed little movement later in the morning. The Sensodyne maker bought 14.29 million shares to cancel them, according to a June 22 filing. The buyback ran from June 16 to June 18. Venue-level data shows the group spent about 47.5 million pounds with an average price of 332.4 pence, around 2.6% under the latest price.

Haleon PLC starts the week still lagging after a broker downgrade put its U.S. recovery in doubt. Shares finished Friday little changed at 334p as trading wrapped up in London. No real shift this week. Haleon touched 341.9p Monday, then couldn’t finish above 335p for the next four days. Buyers still holding back after the fall seen this year.

Haleon PLC traded higher Friday, shaking off a 0.35% drop in the FTSE 100 as investors digested this week’s broker calls on the Sensodyne maker. Last available market data showed Haleon at around 334.5 pence, up 0.2%. No new trading update explained the move. Haleon’s latest regulatory post was a June 15 share-purchase notice, so shares traded on market positioning and debate about the speed of its U.S. business recovery.

Haleon shares fell in London on Wednesday as a new broker downgrade weighed on the Sensodyne owner. The company is still working to reassure investors that sluggish U.S. demand and slow cold-and-flu sales will not impact growth in 2026. Haleon shares last dealt at 332.45 pence, off 0.26%, based on a Cboe Europe estimate on MarketScreener. The stock is now down 1.66% in the past five days and has dropped 11.29% since the year began. Delayed retail data showed the FTSE 100 trading lower by roughly 0.2%.

Haleon PLC shares dropped Tuesday, slipping to the lower ranks of the FTSE 100 after Rothschild & Co Redburn cut its rating and price target. The stock was at 331.7p/331.9p, down 3.30p or 0.98%, according to Hargreaves Lansdown. The FTSE 100 was up 0.71%. MarketScreener showed Haleon around 332.5p on Cboe Europe, off 0.78%. The fresh downgrade is adding to investor concern over Haleon’s sales growth prospects. Haleon shares fell, though the company is still buying back its own stock. On June 15, Haleon said it repurchased 565,285 ordinary shares for cancellation at a volume-weighted average of 331.9552p, bringing voting ordinary shares down to 8.83 billion after the trade settles. Buybacks like this shrink the share count and may lift

Haleon PLC dipped in London Monday, down 0.12% at 336.40p as of 15:05 BST. The FTSE 100 consumer-health stock kept slipping as investors stay cautious after a rocky start in 2026. Sellers nudged the price down but no fresh earnings news or major headlines. Trading volume was light at 7.14 million shares, according to Google Finance, well below the typical 23.55 million. No sign of heavy selling. Haleon bought back 565,285 ordinary shares for cancellation at an average price of 331.9552p each in its March buyback program. Once the deal settles, the company will have 8.83 billion ordinary shares with voting rights left. Fewer shares in issue can lift EPS if profits hold.

Haleon PLC finished Friday’s London session up 0.84% at about 336.8p. The stock hit an intraday high of 337.4p, according to AJ Bell, as the FTSE 100 added 1.63%. There were about 19.0 million shares traded. Haleon’s market cap stands near £29.74 billion. The P/E ratio was 18.21, per AJ Bell, a standard measure comparing share price to earnings. Haleon has seen shares trade mostly on Friday’s market rally and its ongoing buyback plan, with no major earnings updates in recent sessions. The group is listed in London and New York. Investors have also been watching the credibility of Haleon’s 2026 guidance. Its U.S. ADRs finished Friday nearly flat at $9.13, the latest available quote.

Haleon PLC picked up 0.60% in London on Friday, trading at 336.00p at 3:00 p.m. after starting the session at 332.30p. Shares moved in a 331.40p to 337.40p range, according to Google Finance. Investors looked at Haleon's new India manufacturing initiative alongside signs of slower growth in some of its consumer health lines. The price stayed under the 52-week high of 416.10p. The price-to-earnings ratio hovered around 18. Haleon shares are moving as the company keeps working to show investors it can speed up growth after its slow start since splitting from GSK. The company behind Sensodyne, Panadol, Advil and Centrum reported in April that first-quarter organic revenue rose 2.2%. That’s with price up 2.4% and volume off 0.2%. Oral

Haleon shares ticked up in London on Wednesday. Investors looked at a new £175 million India expansion and renewed buybacks, balancing that with a share price that had fallen earlier this week. The company, which owns Sensodyne and Advil, changed hands at 336.10p/336.20p, up 0.60p. Shares opened at 338.40p after closing Tuesday at 335.50p. Haleon edged higher on Wednesday after dropping 1.78% to £3.31 on Monday, lagging the FTSE 100’s 0.05% uptick, data from MarketWatch said. The small move up hints investors are weighing the company’s new emerging-market strategy following a softer period for Haleon shares.

Haleon shares lost ground in London on Monday. The Sensodyne maker said it will spend £175 million on its first owned factory in India, betting it can drive more growth in faster-moving markets. The stock was last seen at 334.10 pence, off roughly 0.9% from Friday’s close after starting the session at 339.40 pence, delayed LSEG data via Investors Chronicle showed. Shares are still trading about 20% under the February 52-week high of 416.10 pence.